Partnership Opportunities

Leading CNS pharma and emerging biotechs are rapidly investing into digital technologies to support the transformation of neurological drug development through more objective, frequent, sensitive, and less invasive measures of movement, speech, and cognition. At the cusp of their implementation into translational and clinical studies, the field still needs to overcome the teething issues to achieve translatable, scalable, and accepted digital neurological biomarkers.

2023 was the time to secure new business and form connections with the top companies and new faces revolutionizing clinical assessments in neuroscience translational development.

Don’t miss your opportunity to join this positive audience of digital health experts looking to discover exciting new technologies and devices and clinical innovation leaders seeking novel solutions to modernize their neurological candidate pipelines.

2023 Partners

nl-light-logo (002)
Red Nucleus logo
Cognivuelogo_color_RGB_Reg_R (22)

CNS Pharma and Biotech Companies Seek:

Medical device and software providers for digital clinical assessments

Wearable technologies and sensors to facilitate sensitive, remote patient data collection

Early-stage patients to test efficacy in promising emerging drug candidates

Clinical CROs with expertise in digital health

Decentralized clinical trials specialists to facilitate efficient and engaged remote data collection

Novel digital biomarker technology to measure speech, cognition, movement, and sleep to monitor neurological disease progression

Why Partner?

  • Network with biopharma key opinion leaders and decision-makers at the forefront of neurological digital biomarker and endpoint development to forge new business opportunities
  • Secure your company as an innovative field leader by presenting your product or service to an engaged audience of translational digital health experts
  • Meet new and upcoming neuroscience companies currently in translational development, yet to select long-term commercial partners